Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2019 April;110(2) > Minerva Medica 2019 April;110(2):139-56

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Medica 2019 April;110(2):139-56

DOI: 10.23736/S0026-4806.18.05874-3

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Clinical use of cardiac troponin for acute cardiac care and emerging opportunities in the outpatient setting

Yader SANDOVAL 1 , Korosh SHARAIN 1, Amy K. SAENGER 2, 3, Stephen W. SMITH 4, Fred S. APPLE 2, 3, Allan S. JAFFE 1, 5

1 Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; 2 Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA; 3 Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, Minneapolis, MN, USA; 4 Department of Emergency Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN, USA; 5 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA



Cardiac troponin (cTn) testing has evolved significantly in recent times. Because of increased sensitivity, its use has shifted from a marker used to help diagnose acute myocardial infarction (MI) to a marker than can be used in the outpatient setting, as well as for both detection of myocardial injury and risk-stratification. Its main role remains in the diagnosis of acute MI and the risk-stratification of patients presenting with suspected acute coronary syndrome. The analytical improvements in assays leading to precise high-sensitivity cTn assays have contributed to the development of numerous strategies to identify patients at both low- and high-risk for acute MI within a few hours. These approaches should reduce overcrowding in the emergency room and expedite triaging. The ability of measuring cTn in most patients using high-sensitivity (hs) assays has allowed for the opportunity to examine its use in the detection of cardiotoxicity in patients undergoing chemotherapy, as well as exploring the application in both primary and secondary prevention of coronary artery disease. This particular field of research has become increasingly complex, partly due to the numerous cTn assays available (I and T; point-of-care, contemporary, hs) and an array of approaches in which one can use the test. The purpose of this document is to summarize the analytical and clinical information relevant to cTn assays, in particular, hs-cTn assays, and describe present and future opportunities for use of cTn in acute cardiac care and in the outpatient setting.


KEY WORDS: Troponin - Myocardial infarction - Myocardial reperfusion injury

inizio pagina